Mannkind Corporation recorded a cumulative net loss of $-44 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 86 other companies achieving higher income per employee. While Mannkind's total ranking has deteriorated compared to the previous quarter from 1453 to 2754.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

MNKD Net Income per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Net Income Change	-	-	-	-30.87 %	-
Net Income per Employee (TTM) $	-73,672	-40,395	9,904	49,380	55,402
MNKD's Total Ranking	# 2754	# 1453	# 695	# 495	#
Seq. Net Income Change	-	-	-	1095.36 %	-94.92 %

MNKD Company Profile >> Back to MNKD Efficiency Comparisons >> Compare MNKD Net Income per Employee to its Competitors

MNKD Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 87
Healthcare Sector	# 269
Overall Market	# 2754

Net Income per Employee Statistics
High	Average	Low
$ 226,711	$ -142,028	$ -622,373
(Mar 31 2017)		(Dec 31 2015)

News about Mannkind Corporation Income per employee

MannKind Repays Certain Debt Obligations A Turning Point for the Company

In a recent press release, MannKind Corporation proudly announced that it has successfully repaid all outstanding indebtedness under its credit and security agreement with MidCap Financial Trust, as well as its convertible promissory note issued to Mann Group LLC. This news comes as a significant step forward for the company, which has been focused on developing and commercializing inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases. However, the journey hasn t been without challenges, as MannKind recorded a cumulative net loss of $-31 million during the 12 months leading up to the third quarter of 2023.
Positive Debt Repayment:
MannKind Corporation s recent achievement of full repayment of its outstanding debt obligations is undoubtedly a positive development for the company. By honoring its financial commitments, MannKind demonstrates its commitment to fiscal responsibility and stability. Repaying the credit and security agreement with MidCap Financial Trust reflects MannKind s ability to manage its financial obligations effectively, instilling confidence in investors and stakeholders. Furthermore, settling the convertible promissory note issued to Mann Group LLC helps improve the company s financial position and may potentially create room for future growth and investment opportunities.

Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector

Income per Employee

Income 12 month ending Jun 30 2026

Number of Employees Jun 30 2026

Date modified: 2026-09-10T16:27:21+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.